[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603764":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Questionnaire","This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.",[13],{"name":14,"affiliation":5,"role":15},"Victoria E Banuchi, MD","STUDY_DIRECTOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","346-217-8668","vebanuchi@mdanderson.org",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-95.36327,29.76328,{"lat":34,"lon":33},[37,39],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":38},"VEBanuchi@mdanderson.org",{"name":14,"role":40,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100603764","radiofrequency-ablation-for-management-of-benignindeterminate-thyroid-nodules-and-low-risk-papillary-thyroid-cancers-100603764",false,"NCT07140757","Radiofrequency Ablation for Management of Benign\u002FIndeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers","Eligibility Criteria\n\n1. Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC\n2. Participant is over 18 years and is either not a surgical candidate or has declined surgery.\n3. Capable and willing to provide written informed consent\n4. Participant has one of the following diagnoses:\n\n   * Biopsy-proven benign thyroid nodules causing compressive and\u002For cosmetic symptoms who are requesting treatment,\n   * Biopsy-proven indeterminate nodules (AUS or follicular neoplasm)\n   * Papillary thyroid carcinoma (PTC) without metastasis\n   * Locally recurrent thyroid cancer (\\\u003C 2 cm).\n\nExclusion Criteria\n\n1. Participants meeting any of the following criteria will be excluded:\n2. Participants considered unsuitable for RFA by the treating physician","ALL","18 Years",{"count":52,"type":53},50,"ESTIMATED","OBSERVATIONAL","To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.",[57,58,59],"Low Risk","Papillary Thyroid Cancer","Radiofrequency Ablation","2026-03-10",{"date":62,"type":63},"2026-03-11","ACTUAL",{"date":65,"type":63},"2025-08-18",{"date":67,"type":53},"2030-12-31",{"name":5,"class":6},1]